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Abstract
On March 19, 2008 a Symposium on Pathophysiology of Ageing and Age-Related Diseases was held
i n  P a l e r m o ,  I t a l y .  T h e  l e c t u r e  o f  D .  M a r i  o n  Hemostasis and ageing is summarized herein.
Physiological ageing is associated with increased plasma levels of many proteins of blood
coagulation together with fibrinolysis impairment. This may be of great concern in view of the
known association between vascular and thromboembolic diseases and ageing. On the other hand,
centenarians are characterized by a state of hypercoagulability and possession of several high-risk
alleles and well-known atherothrombotic risk markers but this appears to be compatible with
longevity and/or health. Parameters considered risk factors for atherosclerotic vascular diseases in
young people may lose their biological significance in advanced age and assume a different role.
Background
On March 19, 2008 a Symposium on Pathophysiology of
Ageing and Age-Related Diseases was held in Palermo,
Italy. The lecture of D. Mari on Hemostasis and ageing is
summarized herein. Physiological ageing is associated
with increased plasma levels of many proteins of blood
coagulation, with fibrinolysis impairment. This may be of
great concern in view of the known association between
vascular and thromboembolic diseases and ageing.
Pro-thrombotic clotting factors
The plasma concentrations of several clotting factors,
namely fibrinogen, factor VII, factor VIII, von Willebrand
factor (VWF), factor IX, factor XII, high molecular-weight
kininogen, and prekallikrein increase with progressing
age in healthy [1]. Meade et al [2] had shown in a popu-
lation study of subjects, aged 53–64 years, significantly
higher levels of fibrinogen (300 mg/dL) than those found
in younger subjects aged 20 (250 mg/dL). As a whole, an
increment of plasma fibrinogen level by 10 mg/dL for
each decade can be expected in healthy subjects. The con-
tribution of fibrinogen to cause thrombosis is not fully
elucidated. Fibrinogen, moreover, is a molecule that plays
a role in acute-phase inflammation and fibrinogen levels
increase in response to interleukin-6 and both are strongly
correlated with ageing [3]. Factor VII which is not an acute
phase reactant, triggers the coagulation cascade when cir-
culating factor VII reacts with tissue factor that is usually
not expressed in the intact vasculature. Factor VII plasma
levels progressively increase with age, from a mean of 95
units/dL in subjects of 20 years old to over 110 units/dL
in subjects over 50. Thrombotic disorders have been
shown to be more frequent in subjects with higher plasma
levels of factor VII but the data have not been confirmed
in other studies [4]. Unfortunately there are differences in
factor VII coagulant assay methodologies. Factor VIII,
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another acute phase protein, acting as a cofactor in the
activation of factor X promoted by factor IXa, progres-
sively increases with age, reaching a mean of over 200
units/dL in the healthy subjects over sixty. The study of
variation of the concentration of the active products of the
coagulation factors (not of the concentration of the single
factor, i.e. the hypercoagulability) is very important to
investigate the relationship between haemostasis and age-
ing. With advancing age many individuals, who are other-
wise normal, show laboratory evidence of heightened
coagulation enzyme activity, i.e., hypercoagulability, as
detected by elevated plasma levels of prothrombin frag-
ment 1 +2 (F1+2), Fibrinopeptide A (FpA), Thrombin-
antithrombin complex (TAT) and D-dimer (D-D). Pro-
thrombin fragment 1 +2 is a measure of the cleavage of
prothrombin by activated factor X (factor Xa) being
released from the amino terminal portion of the molecule
during its conversion to thrombin. FpA is a measure of the
formation of fibrin being released from the α-chain of
fibrinogen when thrombin converts fibrinogen to fibrin.
TAT is a measure of thrombin generation and neutraliza-
tion by antithrombin. DD is a stable degradation product
of cross linked fibrin, a marker of endogenous fibrinoly-
sis. The levels of factor IX and factor X activation peptides
also increase with advancing age [5].
Physiological inhibitors of blood coagulation
The main physiological inhibitors of blood coagulation
are natural anticoagulants produced by the liver and circu-
lating in the plasma, antithrombin III, heparin cofactor II,
the protein C-protein S system, and tissue factor pathway
inhibitor (TFPI). The increased activation of the age-
related coagulation is not due to a decrease in the main
inhibitor of the tissue factor pathway, TFPI, which
increases with ageing. The behaviour pattern of TFPI is
gender dependent; in women, statistically significant
increases in the plasma concentration of TFPI with age
have been observed, paralleling the rise in factor VII. No
significant age-related change in TFPI has been found in
men [6]. Protein C levels are normal in the elderly and lev-
els of protein C activation peptides are increased as well
with age [5], excluding that a reduced activity of the
endothelial thrombomodulin can trigger the activation of
the coagulation. Hypercoagulability in apparently normal
males of increasing age is not supported by the decreased
functional activity of the antithrombin III per se. The
occurrence of menopause significant increases anti-
thrombin III levels, but the increased generation of acti-
vated factor X could depend on a minor efficiency of the
inhibitory system of ATIII, due to a deficient displacement
of the endothelial glycoasaminoglycans modulating the
ATIII activity in vivo [1]. As with other epidemiological
studies, Lowe et al [7] in the course of the Third Glasgow
MONICA Survey observed that the median antithrombin
levels decreased in male elderly, but increased after men-
opause in women before falling again at an older age. The
plasma concentration of free protein S increased with age-
ing; in the healthy blood donors free protein S levels rose
from 86% in subjects under 40 years to 99% in subjects
over 40 years of age. Recently data from the Cardiovascu-
lar Health Study have assessed the associations of com-
mon polymorphisms of protein C (PROC), protein S
(PROS1) and soluble plasma protein C receptor (sEPCR)
and plasma protein C, soluble protein C receptor and pro-
tein S levels measured in a sub-sample of 336 participants
at study entry [mean age 77 ± 7.4 (65–98), 47% female].
The results of this study showed that the PROCR
Ser219Gly polymorphism (rs867186) was strongly asso-
ciated with higher sEPCR levels, explaining 75% of the
phenotypic variation. The Ser219Gly variant was also
associated with higher levels of circulating protein C anti-
gen. The minor alleles of PROC rs2069901 and PROS1
rs4857343 were weakly associated with lower protein C
and free protein S levels, respectively. There was no asso-
ciation between PROCR Ser219Gly and risk of coronary
heat disease, stroke, or mortality. The minor allele of
another common PROCR tagSNP, rs2069948, was associ-
ated with lymphoid PROCR mRNA expression and with
increased risk of incident stroke and all-cause mortality,
and decreased healthy survival during follow-up [8].
Heparin cofactor II (HCII), a serine protease inhibitor
(serpin), inhibits thrombin actions after binding to der-
matan sulphate at injured arterial walls and may nega-
tively regulate thrombin actions in vascular walls. With
the use of ultrasound imaging of the carotid artery, a study
performed in 306 Japanese elderly individuals (154 men
and 152 women; age, 40 to 91 years; 68.9 +/- 11.1 years,
mean +/- SD) demonstrated that plasma HCII activity
decreased with age and negatively correlates with the
severity of carotid atherosclerosis. Then the HCII may be
identified as a novel independent protective factor against
carotid atherosclerosis [9].
FV Leiden
Activated protein C is the underlying cause of the most
prevalent inherited thrombophilia in individuals of Euro-
pean descent. The majority of the patients carry a single
point mutation in the gene encoding factor V, an impor-
tant protein in the clotting coagulation system and carri-
ers of the mutation are at increased risk for venous
thromboembolism [VTE], pregnancy complications, cere-
bral vein thrombosis, and possibly early myocardial inf-
arction with normal coronary anatomy. Based on the
increased risk of VTE events in persons with the FV Leiden
gene, one might assume that persons who carry the FV Lei-
den mutation have a shortened life expectancy compared
with those without the mutation. Studies on octogenari-
ans and centenarians in Europe, however, suggest a nor-
mal life span for FV Leiden carriers. In 3 studies of people
older than 80 years old living in Italy [10], Denmark [11]Immunity & Ageing 2008, 5:12 http://www.immunityageing.com/content/5/1/12
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and the United Kingdom [12] the prevalence of the FV Lei-
den gene in the elderly population was similar to the prev-
alence of the FV Leiden gene in the general population. If
FV Leiden carriers were dying at a younger age from VTE
events, then the expected prevalence of the FV Leiden gene
in an older age group should be lower. In a population-
based mortality study of octogenarians living in Leiden,
660 patients were observed for 10 years. The relative risk
of mortality in FV Leiden carriers was identical to that in
no carriers [13].
Fibrinolyis
Fibrinolysis activity is impaired in the elderly, particularly
due to an increase in plasminogen activator inhibitor 1
(PAI-1) levels. The synthesis of PAI-1 is increased in acti-
vated or injured endothelial cells and smooth muscle
cells, and abundant PAI-1 is also secreted by activated
platelets. The increased expression of this potent inhibitor
in vivo will suppress the normal fibrinolytic system and
create a prothrombotic state, resulting in pathological
fibrin deposition followed by tissue damage. Fibrinolytic
activity decreased significantly in the middle-aged group
as shown by a prolongation of the ECLT (P < 0.01) and
PAI-1, although not significantly, increased by approxi-
mately 100%, whereas tissue plasminogen activator (t-
PA) significantly increased in the middle-aged group (P <
0.01) [14]. In aged subjects plasma PAI-1 levels correlated
with the degree of insulin resistance (r = 0.61, P < 0.001),
fasting plasma triglycerides (r = 0.74, P < 0.001) and age
(r = 0.33, P < 0.001) [15]. Increases in PAI-1 have also
been observed in senescent human umbilical vein
endothelial cells. Genotypes for PAI-1-675 4G/5G
appeared to be associated with lower non-cardiovascular
mortality in men, but with greater cardiovascular mortal-
ity in women in the Cardiovascular Health Study [16].
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) is a
228 plasma carboxypeptidase that regulates fibrinolysis
by removing the C-terminal lysine and arginine residues
from fibrin, that are required for efficient plasmin forma-
tion. Cardiovascular Health Study emphasized the role of
TAFI 438 A/A genotype in predicting mortality in all cases,
which is decreased in white men followed up for 10 years,
the mean age at study entry was 73 years. The additional
years of life are 0.9 (95% CI 02–1.9 years) or 1.1 addi-
tional years of quality of life (95% CI 02–2.1 years), more
than men with the 438G allele. No significant statistically
effects are associated to TAFI 438 G/A in women. TAFI
when activated can cleave several substrates and partici-
pates in the regulation of inflammation [16]. This TAFI
438 A/A genotype may have provided our ancestors with
enhanced anti-inflammatory and antithrombotic mecha-
nisms, to improve wound healing and facilitate reproduc-
tion. TAFI may be one of the genes selected because they
confer a reproductive advantage early in life and may have
harmful effects in the post-reproductive period; negative
selection against these harmful effects fails because the
force of natural selection declines with age [17].
The centenarians
During the last century, preventive medicine and better
living standard in the early stage of life have ameliorated
responses to short-term infections, with delayed adverse
effects during ageing. Mari et al [18] were the first to meas-
ure parameters of coagulation and fibrinolysis in centenar-
ians and in older [51–69 years old] and younger controls
[18–50 years old]. Older controls had slightly higher val-
ues of several coagulation and fibrinolysis measurement
than younger controls. Centenarians have a state of hyper-
coagulability with striking signs of high coagulation
enzyme activity, as assessed directly by measuring factor
VIIa in plasma (p < 0.01, compared with either control
group) or indirectly by measuring the peptides released
following the activation of prothrombin, or factor IX, or
factor X (all p < 0.001). In addition, thrombin activity and
enhanced formation of fibrin is evidenced by high circu-
lating levels of fibrinopeptide A (p > 0.001) and second-
ary high hyperfibrinolysis, as reflected by elevated levels
of D-dimer and of plasmin-antiplasmin complexes (both
> 0.001). VWF, a well-known atherothrombotic risk
marker is extremely high in centenarians. Fifty-one per-
cent of centenarians have a reduction of the relative pro-
portion of high molecular weight multimers [HMW];
furthermore VWF-cleaving protease was lower than in
young controls [19]. Centenarians have anti-aCL and anti-
beta-2GPI antibodies with a pattern comparable to that
present in sera from patients suffering from the antiphos-
pholipid syndrome. In spite of the presence of antibodies
comparable to those found in patients with the anti-phos-
pholipids syndrome, no vascular events were reported
suggesting the presence of unknown protective factors
and/or the lack of triggering factors [20]. The study on Ital-
ian centenarians suggests that the 4G allele carriers
reached longevity despite high circulating PAI-1 level.
Centenarians have a paradoxically significantly higher fre-
quency than young individuals of the high-risk genetic
markers mutant factor V (Arg506Gln) and prothrombin
gene G20210A mutation [21,22]. Thus, the state of hyper-
coagulability and the possession of several high-risk alle-
les and well-known atherothrombotic risk markers appear
to be compatible with longevity and/or health.
Conclusion
In the oldest old, the cardiovascular risk factors could play
a different role that in young-adult subjects: for example,
high total cholesterol concentrations are associated with
longevity owing to lower mortality from cancer and infec-
tion [23]. Candore et al [24] demonstrated the differentPublish with BioMed Central    and   every 
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role of some proinflammatory alleles, such as pyrin and
CCR5, in acute myocardial infarction and longevity. The
results support the hypothesis that the genetic back-
ground favouring cardiovascular diseases is detrimental to
longevity. Data about the hemostasis profile of centenari-
ans once again emphasized the need for a multidiscipli-
nary approach if we wish to understand the mechanisms
of successful ageing and to establish the contribution of
unknown protective genes.
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